Rodrigo Cadierno-Entrialgo
Pamplona, NC, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Targeted KRASG12V Degradation In Vivo Elicits Lung Adenocarcinoma Regression with Subsequent Relapse from Dysregulated Proteolysis.
Journal: Cancer research
Published: November 12, 2025
Targeted KRASG12V Degradation in vivo Elicits Lung Adenocarcinoma Regression with Subsequent Relapse from Dysregulated Proteolysis.
Journal: Cancer research
Published: November 12, 2025
Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma.
Journal: Cancer cell
Published: June 18, 2025
The C5a/C5aR1 Axis Promotes Migration of Tolerogenic Dendritic Cells to Lymph Nodes, Impairing the Anticancer Immune Response.
Journal: Cancer immunology research
Published: March 15, 2024
Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer.
Journal: Nature communications
Published: December 13, 2022
LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 14, 2022
Antiproliferative and palliative activity of flavonoids in colorectal cancer.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: July 27, 2021
FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted.
Journal: Journal of hepatology
Published: July 30, 2020
Liver Kinase B1 (LKB1) Loss Has its p-ERKs: ERK Inactivation as a Vulnerability in NSCLC With LKB1 Mutations.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: November 19, 2019
The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas.
Journal: The Journal of clinical investigation
Published: March 21, 2019
Last Updated: 09/26/2026